Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsDown regulation of virulence factors of Pseudomonas aeruginosa by salicylic acid attenuates its virulence on Arabidopsis thaliana and Caenorhabditis elegansInitiating a crystallographic analysis of recombinant (S)-2-hydroxypropylphosphonic acid epoxidase from Streptomyces wedmorensisThe glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosaA cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis.Fosfomycin: use beyond urinary tract and gastrointestinal infections.Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database.Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.The problems of antibiotic resistance in cystic fibrosis and solutions.Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosaFosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10.Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria.Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin.Fosfomycin: Pharmacological, Clinical and Future Perspectives.
P2860
Q21131083-02D1356E-4B97-46F1-80F1-119FA98171CFQ24534761-665041BA-051C-4141-8028-042C57CE4488Q24675383-F85ACC3D-873A-42B6-9220-0B3E43D93EDDQ28492495-60B9F53B-5127-4B1C-8A70-2B6E79755FC4Q31811697-47F3C9BE-1F95-425A-A10B-A35119B5E3EAQ34774778-66B8F166-C9FD-446C-932C-A1A0CFDCEC25Q35105960-2F1BF7EB-77CE-4F92-A0F8-6F513C15B65EQ36363257-3CAF73F1-0CAF-49FB-A353-EAAE82CFFC1BQ36670892-4330912B-C689-447E-BB0C-4BA988FAE309Q38101836-0424AC8A-49AC-43F7-B7EA-CA97D9EE3790Q38208281-AF3F8E20-0F54-4F30-B4D6-980DD37D883EQ38300820-3301A143-4A68-4715-A723-3347FCF0E57CQ38447194-426C907B-078C-4565-81AF-4522CEE791C1Q40166194-75EB009F-BB6E-4AEC-B87A-CA033F4928D1Q40476281-DD2CE7DE-242B-41EA-895B-77F8B9C0021AQ40697349-2241F70A-546E-4A37-A6D8-A78A81F481ABQ40698278-F72D8388-BD78-4DFD-A71C-9C7C5AF9CF7CQ41812492-40D12126-21F5-491C-9DB3-CECFFD4C75D0Q42261308-7E95CAC6-4643-4A07-9C49-A766120A3D4FQ42550334-410B7462-5BF8-4A6C-B544-5792875AE11FQ43662701-8FA8207A-72F8-4E3B-B519-B1A0742C2EE3Q46832064-E0338C8C-0DCB-4E76-AB79-A18DB72E58B1Q47136072-CD07975E-8116-429D-A226-467A233F8435
P2860
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@ast
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@en
type
label
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@ast
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@en
prefLabel
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@ast
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@en
P2093
P921
P1476
Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
@en
P2093
P356
10.1016/S1569-1993(02)00143-1
P577
2003-03-01T00:00:00Z